Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biocept Inc (NQ: BIOC )

0.6750 -0.0350 (-4.93%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 7, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 114,500
Open 0.7100
Bid (Size) 0.6501 (13)
Ask (Size) 0.7088 (4)
Prev. Close 0.7100
Today's Range 0.6700 - 0.7100
52wk Range 0.6700 - 4.250
Shares Outstanding 17,058,770
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Biocept Reports Third Quarter 2022 Financial Results
From Biocept, Inc.
Via Business Wire
Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors
From Biocept, Inc.
Via Business Wire

Performance

YTD
-83.00%
-83.00%
1 Month
-20.34%
-20.34%
3 Month
-32.36%
-32.36%
6 Month
-57.01%
-57.01%
1 Year
-81.76%
-81.76%

More News

Read More
Biocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous System
From Biocept, Inc.
Via Business Wire
Biocept Reports Second Quarter 2022 Financial Results
From Biocept, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Biocept to Present at the LD Micro Main Event XV
From Biocept, Inc.
Via Business Wire
Biocept Expands Commercial Offering of CNSide™ Assay to Most Cancers that Metastasize to the Central Nervous System
From Biocept, Inc.
Via Business Wire
Biocept to Host KOL Webinar Today to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
From Biocept, Inc.
Via Business Wire
Biocept to Host Key Opinion Leader Webinar on October 14 to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
From Biocept, Inc.
Via Business Wire
Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday
Via Benzinga
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Biocept, Inc.
Via Business Wire
Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q
From Biocept, Inc.
Via Business Wire
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
From Biocept, Inc.
Via Business Wire
Biocept Appoints RSM as Independent Auditor
From Biocept, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Biocept to Hold Business Strategy Conference Call Today
From Biocept, Inc.
Via Business Wire
Biocept's Return On Capital Employed Overview
Via Benzinga
Biocept Reports First Quarter 2022 Financial Results
From Biocept, Inc.
Via Business Wire
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Via Benzinga
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
From Biocept, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.